Filing Analysis
KALA BIO, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. Notably, the company is ineligible for the standard 180-day compliance period because it executed a 1-for-50 reverse stock split in May 2026.
🚩 Red Flags
- Ineligibility for standard compliance period due to recent reverse split (Red Flag Escalator).
- Failure to maintain minimum bid price requirement.
- Recent 1-for-50 reverse stock split (Red Flag Escalator).
- Risk of delisting if the appeal is unsuccessful.
📋 Key Facts
- Nasdaq Staff Determination Letter received on August 27, 2026.
- Stock closed below $1.00 for 30 consecutive business days (July 16, 2026 – August 26, 2026).
- Company is ineligible for a standard 180-day compliance period per Nasdaq Rule 5810(c)(3)(A)(iv) due to a prior reverse split.
- Company executed a 1-for-50 reverse stock split on May 11, 2026.
- The company intends to request a hearing before the Nasdaq Hearings Panel to appeal the determination.
Kala Bio, Inc. filed an 8-K to provide a legal opinion regarding the validity of securities being offered under a prospectus supplement related to its existing S-3 registration statement.
📋 Key Facts
- The filing is pursuant to Item 8.01 (Other Events).
- Relates to a prospectus supplement filed under Rule 424(b) of the Securities Act of 1933.
- Securities are being offered pursuant to an effective Registration Statement on Form S-3 (File No. 333-295667).
- Includes a legal opinion from Haynes and Boone, LLP as Exhibit 5.1.
Kala Bio has replaced its auditor, Deloitte & Touche LLP, with HTL International, LLC. Additionally, six directors have tendered conditional resignations effective upon the approval of specific shareholder proposals regarding stock conversion and authorized share increases.
🚩 Red Flags
- Auditor change from a Big Four firm (Deloitte) to a smaller firm (HTL International) can sometimes indicate difficulty in maintaining high-level audit oversight.
- Mass resignation of six directors contingent on specific capital structure changes suggests significant upcoming shifts in corporate governance and ownership control.
📋 Key Facts
- Dismissal of Deloitte & Touche LLP as independent registered public accounting firm approved by Audit Committee.
- Engagement of HTL International, LLC for fiscal year ending December 31, 2025.
- Six directors (Marjan Farid, Andrew I. Koven, C. Daniel Myers, Todd Bazmore, Mark Iwicki, and Howard B. Rosen) tendered conditional resignations on Dec 19, 2025.
- Resignations are contingent upon shareholder approval of Proposal 4 (preferred stock conversion) and Proposal 5 (increase in authorized shares).
- The company states the director departures are not due to disagreements regarding operations, policies, or practices.
KALA BIO, Inc. has dismissed its independent registered public accounting firm, Deloitte & Touche LLP, effective December 15, 2025. As of the filing date, the company has not yet appointed a successor auditor.
🚩 Red Flags
- Auditor change without a successor in place can lead to delays in future financial filings and potential non-compliance with SEC reporting timelines.
- The absence of a replacement auditor is a common precursor to administrative or reporting delays for micro-cap companies.
📋 Key Facts
- Deloitte & Touche LLP was dismissed on December 15, 2025.
- Audit reports for fiscal years ended Dec 31, 2024, and Dec 31, 2023, contained no adverse opinions, disclaimers, or qualifications.
- The company reported no disagreements with Deloitte regarding accounting principles, practices, financial statement disclosure, or auditing scope/procedures.
- No new independent registered public accounting firm has been appointed as of the filing date.
Kala Bio, Inc. reports a significant restructuring of its leadership and capital structure involving investor David Lazar. This includes Mr. Lazar's appointment as CEO/Chair following a $6.0 million preferred stock placement, alongside the transfer of his rights in certain shares to an unaffiliated Panamanian entity.
🚩 Red Flags
- Related-party transaction: The primary investor (David Lazar) has assumed total control as CEO and Board Chair.
- Complex capital structure involving multiple series of convertible preferred stock issued to a single insider.
- Potential conflict of interest: A principal of the entity that acquired Mr. Lazar's rights is now acting as a consultant for the company.
- High concentration of control/risk due to the interlocking roles of investor and executive leadership.
📋 Key Facts
- Annual Meeting of stockholders scheduled for January 30, 2026.
- David Lazar appointed as CEO and Principal Financial Officer; also elected to Board as Class II director and Chair of the Board.
- Company entered a $375,000 Convertible Loan Agreement with David Lazar on Nov 9, 2025.
- Securities Purchase Agreement for up to $6.0 million in Series AA and Series AAA Preferred Shares with David Lazar.
- Series AA Preferred Share closing occurred on Nov 24, 2025 (900,000 shares at $2.00/share).
- David Lazar transferred his rights to purchase Series AAA Preferred Shares to AK Holdings Group Inc. (a Panamanian company).
- A principal of the Lazar Transferee was engaged as a consultant on Dec 11, 2025, to assist with strategic alternative transactions.
KALA BIO, Inc. completed a $10 million registered direct offering consisting of 900,000 common shares and pre-funded warrants to an institutional investor at $1.00 per share. The net proceeds are intended for debt repayment and general corporate purposes.
🚩 Red Flags
- Significant dilution potential due to the large number of pre-funded warrant shares (9.1M) relative to the common shares issued (900k).
- High placement agent fee (8.0% of gross proceeds).
- The offering is a registered direct offering, often used by micro-cap companies needing immediate liquidity.
📋 Key Facts
- Offering size: $10 million gross proceeds.
- Structure: 900,000 common shares and pre-funded warrants to purchase up to 9,100,000 additional shares.
- Price: $1.00 per share (less $0.0001 for pre-funded warrants).
- Warrant terms: Initial exercise price of $0.0001; subject to ownership restrictions (4.99% or 9.99%).
- Placement Agent: H.C. Wainwright & Co., LLC, earning an 8.0% cash fee plus expenses.
- Use of proceeds: Repayment of indebtedness and general corporate purposes.
KALA BIO is undergoing an extreme liquidity crisis involving a default on a major loan, asset foreclosure by the lender (Oxford Finance), and a massive restructuring of its capital structure. The company has entered into a $6.0 million private placement with David Lazar to settle existing debts and fund operations, which includes significant equity issuance and potential board control shifts.
🚩 Red Flags
- Extreme liquidity crisis: Lender (Oxford) had swept all bank accounts.
- Massive workforce reduction due to inability to meet obligations.
- Highly dilutive financing: Series AAA shares convert at a 420:1 ratio, which is extremely punitive for existing shareholders.
- Debt settlement involves significant equity issuance to the lender (Oxford).
- Investor control: The Investor has rights to nominate up to eight board members and imposes strict operational covenants (no debt, no changes to business nature, etc.).
- Potential delisting risk due to massive dilution and restructuring.
📋 Key Facts
- Company received a Default Notice from Oxford Finance on September 29, 2025.
- Oxford Finance had previously swept substantially all cash resources and initiated foreclosure proceedings.
- The company terminated most employees on October 19, 2025, to preserve minimal cash for payroll/foreclosure costs.
- Entered into a Securities Purchase Agreement with David Lazar (Investor) for up to $6.0 million in Series AA and AAA Preferred Shares.
- First Closing occurred Nov 24, 2025: 900,000 Series AA shares at $2.00/share ($1.8M total).
- Second Closing (expected by March 31, 2026): 2,100,000 Series AAA shares at $2.00/share ($4.2M total).
- Series AAA shares are highly dilutive: each share is initially convertible into 420 shares of Common Stock.
- Settlement with Oxford involves a $2.0 million cash payment and issuance of 1,620,000 shares of Common Stock to settle/reduce debt by $7.0 million.
KALA BIO, Inc. received a deficiency letter from Nasdaq for failing to meet the Minimum Market Value of Listed Securities (MVLS) requirement. The company's market value fell below $35 million for 30 consecutive business days.
🚩 Red Flags
- Delisting notice/deficiency letter from Nasdaq.
- Failure to meet alternative listing standards (equity and net income).
- Market capitalization is significantly below the required threshold, indicating low investor confidence or liquidity issues.
- Potential for delisting if compliance is not achieved by May 2026.
📋 Key Facts
- Received deficiency notice on November 10, 2025.
- Non-compliance with Nasdaq Listing Rule 5550(b)(2) (Minimum MVLS Requirement).
- Market value of listed securities was less than $35 million for the previous 30 consecutive business days.
- Company does not meet alternative standards: stockholders' equity is below $2.5 million and net income failed to meet the $500,000 threshold.
- Compliance deadline (Compliance Date) is May 11, 2026 (180-day period).
- Regaining compliance requires market value to close at $35 million or more for 10 consecutive business days.
Kala Bio entered into a $375,000 convertible loan agreement with an individual investor to fund negotiations for additional investment and the preparation of its overdue 10-Q report. The company is currently facing imminent foreclosure by its primary lender, Oxford Finance LLC, which has already swept substantially all cash resources from the company's accounts.
🚩 Red Flags
- Imminent foreclosure: Oxford Finance LLC has expressed intent to foreclose on all remaining assets.
- Severe liquidity crisis: Primary lender has already swept nearly all cash from bank accounts.
- Extreme capital constraint: The new $375k loan is restricted solely to administrative/negotiation costs and filing overdue reports.
- High-interest debt: 15% simple interest rate on a bridge loan for a company in distress.
- Dependency on single investor: Company is prohibited from seeking other investment offers until Nov 17, 2025.
📋 Key Facts
- Entered into a Convertible Loan Agreement on November 9, 2025, for up to $375,000.
- Loan features a 15% per annum simple interest rate with monthly payments starting December 2025.
- The lender has the right to convert the loan into common stock or receive cash upon an M&A transaction or public offering.
- Proceeds are strictly limited to negotiating additional investment and preparing the Q3 2025 Form 10-Q.
- Company is under a period of exclusivity with this lender until November 17, 2025.
- Oxford Finance LLC has previously swept substantially all cash resources from company bank accounts.
KALA BIO, Inc. is facing imminent liquidation following a foreclosure action by its secured lender, Oxford Finance LLC. The company has ceased development of its primary platform, terminated most employees, and expects delisting from Nasdaq and the inability to meet SEC reporting obligations.
🚩 Red Flags
- Imminent foreclosure on all remaining assets by secured lender Oxford Finance LLC.
- Total loss of liquidity; cash resources have been swept by the lender.
- Likelihood of zero recovery for stockholders or unsecured creditors.
- Expected delisting from Nasdaq.
- Inability to fulfill SEC reporting requirements (10-Q and 10-K).
- Cessation of core business operations (KPI-012 development).
📋 Key Facts
- Oxford Finance LLC has swept substantially all cash resources from the Company's bank accounts.
- The Board terminated all employees on October 19, 2025, except those necessary for the foreclosure process.
- Oxford remains owed approximately $9.6 million after applying swept cash to secured debt claims.
- CEO Todd Bazemore was terminated without cause but will continue as a director and principal executive officer during the wind-down.
- The Company expects its common stock will be delisted from The Nasdaq Capital Market.
- The Company anticipates it will be unable to file upcoming 10-Q (Sept 30, 2025) and 10-K reports.
Kala Bio is undergoing a significant strategic pivot, including the cessation of its KPI-012 development and mesenchymal stem cell platform. The company has implemented a 51% workforce reduction to preserve cash while exploring strategic options.
🚩 Red Flags
- Significant workforce reduction (51%) indicating severe distress/pivot.
- Cessation of primary product development (KPI-012) and platform technology.
- Company is actively 'exploring strategic options,' often a precursor to sale or liquidation.
- High executive turnover risk mitigated only by cash retention payments.
📋 Key Facts
- Ceasing development of KPI-012 and the mesenchymal stem cell secretome platform.
- Workforce reduction of approximately 19 employees, representing ~51% of staff.
- Estimated restructuring costs of $0.4 million in Q4 2025 (severance and benefits).
- Retention agreements signed on October 2, 2025, for CEO Todd Bazemore ($183,750), CFO Mary Reumuth ($136,250), and CMO Kim Brazzell ($145,000).
- Retention payments are subject to clawback if terminated voluntarily or for cause before December 31, 2025.
KALA BIO, Inc. received a notice of default from Oxford Finance LLC on September 29, 2025, regarding its Loan and Security Agreement. The lender has declared all obligations immediately due and payable following an alleged Material Adverse Change.
🚩 Red Flags
- Acceleration of debt: $29.1 million is now due immediately, creating a massive liquidity crisis.
- Material Adverse Change (MAC) trigger: Indicates significant deterioration in company operations or financials.
- Default interest rates apply: Increases the cost of capital significantly during an already distressed period.
- Potential insolvency risk: The immediate demand for $29.1M likely exceeds current cash reserves for a micro-cap biotech.
📋 Key Facts
- Notice of event of default received from Oxford Finance LLC on September 29, 2025.
- The default is based on Section 8.3 (Material Adverse Change) and potentially other undisclosed events.
- Total accelerated obligations amount to $29.1 million plus interest and expenses.
- Interest rates have immediately shifted to the 'Default Rate' as defined in the Loan Agreement.
KALA BIO, Inc. is ceasing development of its lead candidate KPI-012 and mesenchymal stem cell secretome platform following a failed Phase 2b clinical trial (CHASE). The company is implementing a 51% workforce reduction to preserve cash while exploring strategic options and engaging with secured lenders.
🚩 Red Flags
- Clinical trial failure of the primary asset (KPI-012).
- Massive workforce reduction (51% of staff) indicating severe distress.
- Explicit mention of engaging in discussions with a 'secured lender,' suggesting potential debt restructuring or insolvency risk.
- Abandonment of the core technology platform (mesenchymal stem cell secretome).
📋 Key Facts
- KPI-012 CHASE Phase 2b trial failed to meet primary endpoint of complete healing for persistent corneal epithelial defect (PCED).
- Trial failed to achieve statistical significance for key secondary efficacy endpoints vs placebo.
- Company is ceasing development of the KPI-012 program and its mesenchymal stem cell secretome platform.
- Workforce reduction of approximately 19 employees, representing ~51% of staff, expected to complete in Q4 2025.
- The company will engage in discussions with its secured lender regarding strategic options.
KALA BIO, Inc. has announced the scheduling of its 2025 Annual Meeting of Stockholders for December 11, 2025. Due to the meeting date deviating significantly from the anniversary of the previous year's meeting, the company has established specific deadlines for stockholder proposals and director nominations.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is scheduled for December 11, 2025.
- Stockholder proposals under Rule 14a-8 must be received by October 1, 2025, to be included in proxy materials.
- Notice for director nominations or other matters must be received by the Secretary by September 28, 2025.
- The meeting date change triggers specific compliance deadlines under the Company's By-Laws.
KALA BIO, Inc. has appointed Todd Bazemore as Chief Executive Officer, effective August 29, 2025. Mr. Bazemore, who has served as interim CEO since February 2025, will also serve as a Class II director and transition from his role as COO to focus on the CEO position.
🚩 Red Flags
- Significant severance package triggered by 'Change of Control' events, including 24 months of salary and 200% of target bonus.
📋 Key Facts
- Todd Bazemore appointed CEO effective August 29, 2025.
- Bazemore transitions from Chief Operating Officer (COO) to Chief Executive Officer (CEO).
- Bazemore elected as a Class II director until the 2025 Annual Meeting of Stockholders or successor election.
- Annualized base salary set at $655,000 with a target annual incentive bonus of 60.0%.
- Grant of stock option to purchase up to 180,000 shares of common stock, vesting over four years (1/48th monthly).
- Severance terms updated specifically for termination following a Change of Control within a 24-month window.
KALA BIO, Inc. announced its financial results for the second quarter ended June 30, 2025, and provided a general business update via an 8-K filing.
📋 Key Facts
- Report date: August 8, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes results of operations and financial condition under Item 2.02
- A press release was issued as Exhibit 99.1
Kala Bio, Inc. announced the completion of patient enrollment for its CHASE Phase 2b clinical trial evaluating KPI-012 for the treatment of persistent corneal epithelial defect (PCED). The company expects to report topline data from this study in Q3 2025.
📋 Key Facts
- Completed patient enrollment for the CHASE Phase 2b clinical trial.
- Trial evaluates KPI-012 (human mesenchymal stem cell secretome) at two doses: 3 U/mL and 1 U/mL vs. vehicle.
- Study involves 79 patients across 37 sites in the US and Latin America.
- Primary endpoint is complete healing of PCED via corneal fluorescein staining photographs.
- Topline data expected in Q3 2025.
- Positive results could support a Biologics License Application (BLA) to the FDA.
KALA BIO, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025, and provided a general business update.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes results of operations and financial condition updates via Exhibit 99.1.
- The report was signed by Mary Reumuth, CFO.
Kala Bio, Inc. has entered into retention agreements with its Interim CEO, CFO, and Head of R&D/CMO to ensure leadership stability through critical clinical milestones.
🚩 Red Flags
- Use of retention bonuses suggests potential risk of executive turnover during a critical clinical phase.
- The timing is tied specifically to 'topline data' for the CHASE clinical trial, indicating high stakes and binary outcome risk associated with KPI-012.
📋 Key Facts
- Retention agreements signed on April 10, 2025, for key executives: Todd Bazemore (Interim CEO), Mary Reumuth (CFO), and Kim Brazzell, Ph.D. (Head of R&D/CMO).
- Retention bonuses awarded: $281,190 for Bazemore, $234,000 for Reumuth, and $260,000 for Dr. Brazzell.
- Clawback provision: Executives must repay the gross bonus if they leave voluntarily or are terminated for cause before September 30, 2025, or before topline data from the CHASE clinical trial of KPI-012 is announced.
KALA BIO, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2024, alongside a general business and corporate update.
📋 Key Facts
- Reported date: March 31, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- Filing includes results of operations and financial condition updates via Exhibit 99.1
KALA BIO, Inc. announced the immediate resignation of its Chief Executive Officer, Mark Iwicki, effective February 11, 2025. The company has appointed current President and COO Todd Bazemore as interim CEO.
🚩 Red Flags
- Immediate resignation of the CEO is often a signal of internal friction or unexpected strategic shifts.
- Leadership transition in a micro-cap biotech can lead to operational instability during critical clinical/regulatory phases.
📋 Key Facts
- Mark Iwicki resigned as CEO effective February 11, 2025; he will remain as Chair of the Board.
- Todd Bazemore appointed as Interim CEO and principal executive officer, effective immediately.
- Bazemore has served as Company President since December 2021 and COO since November 2017.
- Bazemore's background includes leadership roles at Santhera Pharmaceuticals, Dyax Corp., and Sunovion Pharmaceuticals.
Kala Bio, Inc. entered into a Securities Purchase Agreement to conduct a $10.75 million private placement of Common Stock and Series I Convertible Non-Redeemable Preferred Stock. The offering includes significant registration rights with liquidated damages provisions for the company.
🚩 Red Flags
- Liquidated damages clause: The company must pay pro rata liquidated damages (1.0% per 30-day period) if registration requirements are not met.
- Seniority of capital: Series I Preferred Stock is senior to all Common Stock and junior securities, potentially diluting common shareholders in liquidation scenarios.
- Beneficial Ownership Limitation: Conversion is restricted if it causes the holder to own more than 9.99% (up to 19.99%) of outstanding shares.
📋 Key Facts
- Aggregate gross proceeds: approximately $10.75 million.
- Issuance of 1,340,603 Common Shares at $6.44 per share.
- Issuance of 3,286 Series I Preferred Shares at $644.00 per share.
- Series I Preferred Stock is convertible into 100 shares of common stock per preferred share (subject to adjustments).
- The offering includes a Registration Rights Agreement requiring the company to file a registration statement within 30 days of closing.
- Closing expected on or about December 31, 2024.
KALA BIO, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024, and provided a general business update.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Filing date: November 12, 2024
- The filing includes the announcement of financial results and a general business update via Exhibit 99.1.
Mark S. Blumenkranz, M.D. has resigned from the Board of Directors, the Audit Committee, and the Nominating and Corporate Governance Committee, effective September 23, 2024.
📋 Key Facts
- Resignation date: September 23, 2024
- Departing individual: Mark S. Blumenkranz, M.D.
- Positions vacated: Member of the Board of Directors, Audit Committee, and Nominating and Corporate Governance Committee
- The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
KALA BIO, Inc. announced its financial results for the second quarter ended June 30, 2024, and provided a general business update via an 8-K filing.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Filing date: August 6, 2024
- The filing includes results of operations and financial condition under Item 2.02
- A press release was issued as Exhibit 99.1 containing the full details of the update
Kala Bio, Inc. entered into a Securities Purchase Agreement to conduct a $12.5 million private placement of Common Stock and Series H Convertible Non-Redeemable Preferred Stock. The offering includes significant registration rights and liquidation preferences for the new preferred shares.
🚩 Red Flags
- Issuance of convertible preferred stock (Series H) which can lead to significant dilution upon conversion.
- Liquidation preference for Series H holders that ranks senior to common shareholders.
- Registration rights include liquidated damages clauses, indicating high pressure on the company to maintain registration effectiveness.
- The filing mentions 'Cash Runway' at the end, suggesting a need for immediate capital infusion.
📋 Key Facts
- Aggregate gross proceeds of approximately $12.5 million from institutional investors.
- Issuance of 1,197,314 Common Shares at $5.85 per share.
- Issuance of 9,393 Series H Preferred Shares at $585.00 per share.
- Series H Preferred Stock is convertible into 100 shares of common stock per preferred share (subject to adjustments).
- The Series H Preferred Stock ranks senior to all Common Stock and junior only to 'Senior Securities'.
- Registration rights agreement includes liquidated damages of 1.0% of investment for every 30-day delay in filing/effectiveness.
- Closing is expected on or about June 28, 2024.
KALA BIO, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 11, 2024. The meeting included elections for Class I directors, ratification of auditors, and several shareholder votes regarding compensation and preferred stock conversion.
🚩 Red Flags
- Shareholders rejected proposals (5a, 5b, 5c) that would have granted the Board discretion to increase beneficial ownership limitations for certain preferred stock series.
📋 Key Facts
- Elected Marjan Farid, M.D., Andrew I. Koven, and Gregory D. Perry as Class I directors to three-year terms expiring in 2027.
- Ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Approved the issuance of common stock upon conversion of Series E, F, and G Convertible Non-Redeemable Preferred Stock per Nasdaq Listing Rule 5635(b).
- Shareholders did not approve amendments to allow the Board discretion to increase beneficial ownership limitations for Series E, F, or G preferred stock.
- Approved non-binding advisory vote on executive compensation.
KALA BIO, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024, and provided a general business update.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Filing date: May 14, 2024
- The filing includes results of operations and financial condition updates via Exhibit 99.1.
KALA BIO, Inc. announced its financial results for the fiscal quarter and year ended December 31, 2023, alongside a general business update.
📋 Key Facts
- Financial results released for the quarter and year ended December 31, 2023.
- Filing includes a press release (Exhibit 99.1) containing detailed financial data and business updates.
- Reported via Item 2.02 (Results of Operations and Financial Condition).
KALA BIO, Inc. entered into a Securities Purchase Agreement to issue Series G Convertible Non-Redeemable Preferred Stock in a private placement for approximately $8.6 million. The offering is priced at-the-market under Nasdaq rules and includes restrictive covenants regarding additional debt and equity issuance.
🚩 Red Flags
- Restrictive covenants: Company cannot issue senior/pari passu equity or incur additional debt >$1M without purchaser approval.
- Convertible structure: The Series G stock is convertible into common stock, which can lead to future dilution of existing shareholders.
📋 Key Facts
- Private placement of 10,901 shares of Series G Convertible Non-Redeemable Preferred Stock.
- Aggregate gross proceeds of approximately $8.6 million.
- Preferred Stock Price set at $788.90 per share.
- Series G Preferred Stock is convertible into 100 shares of Common Stock per preferred share (subject to adjustments).
- The offering includes a beneficial ownership limitation preventing conversion if it results in >9.99% ownership (unless adjusted up to 19.99%).
- Closing expected on or about March 26, 2024.
Kala Bio, Inc. provided a corporate overview presentation via its website and announced a target timeline for topline data from its Phase 2b CHASE clinical trial.
🚩 Red Flags
- Forward-looking statements regarding clinical trial timelines carry inherent risks and uncertainties typical of biotech micro-caps.
📋 Key Facts
- Company released a 'Innovation In Ophthalmology - Corporate Overview – March 2024' presentation on its website.
- Targeting topline safety and efficacy data from the CHASE (Corneal Healing After Secretome therapy) Phase 2b clinical trial by the end of 2024.
- The CHASE trial evaluates KPI-012, a human mesenchymal stem cell secretome, for treating persistent corneal epithelial defect.